ライフサイエンスコーパス: alum

1 together with FVIII adsorbed in an adjuvant (alum).

2 juvant-based model in wild-type mice (WT-OVA/alum).

3 us toxoid adsorbed to aluminum hydroxide (TT/Alum).

4 the Hepatitis B virus vaccine formulated in alum.

5 -desacyl-4'-monophosphoryl lipid A (MPL) and alum.

6 ion with an intraperitoneal injection of OVA/alum.

7 monovalent or bivalent vaccines with CpG and alum.

8 ophenol-conjugated chicken gamma-globulin in alum.

9 at were stronger than those induced by Ag in alum.

10 litatively stronger response than GLA, SE or alum.

11 on with ovalbumin (OVA) along with papain or alum.

12 D4 T-cell priming by i.m. injected antigen + alum.

13 ining lymph node in mice immunized i.p. with alum.

14 Host DNA rapidly coats injected alum.

15 grass pollen allergen Phl p 5 together with alum.

16 immunization with ovalbumin (OVA) mixed with alum.

17 exclusively Th2 humoral response elicited by alum.

18 trols in the chronic OVA model without added alum.

19 onophosphoryl lipid A, a TLR-4 agonist, with alum.

20 erformed in the presence of either GLA-SE or alum.

21 pared to vaccinations with soluble VMP001 or alum.

22 p3), is essential for the adjuvant effect of alum.

23 group was immunized with gD2t protein in MPL-alum.

24 owing immunization with Ags in CFA or IFA or alum.

25 yl (NP)-conjugated chicken gamma globulin in alum.

26 ing that both of these cell types can detect alum.

27 e primed and boosted with S. Typhi(F1) or F1-alum.

28 t role for IFN-gamma, even in the setting of alum.

29 s adjuvanted by monophosphoryl lipid A (MPL)-alum.

30 in the mice immunized with either U1 RNA or alum.

31 suggest a mechanism for the adjuvanticity of Alum.

32 ntibodies following three immunizations with alum.

33 somewhat reduces responses to some Ags with alum.

34 nge of Spi2A knockout mice with ovalbumin in alum.

35 ent FLSC proteins or with monomeric gp120 in alum.

36 n response to inflammatory thioglycollate or alum.

37 ody responses were in the 30 microg RSV-PreF/alum, 60 microg RSV-PreF/alum, and 60 microg RSV-PreF/no

38 to allow adsorption onto aluminum hydroxide (alum), a formulation commonly used in vaccines for antig

39 properties, which is highly comparable with alum, a commonly used adjuvant.

40 nts after parenteral administration to mice: alum, a derivative of the heat-labile toxin (LT), and th

41 nus toxoid vaccine adjuvanted with potassium alum, a human hepatitis B vaccine adjuvanted with alumin

42 In this study, we show that Alum activates caspase-1 and induce secretion of mature

43 We have recently shown that alum activates caspase-1 and induces secretion of mature

44 Alum activates the intracellular stress sensors inflamma

45 NA to promote migration of inflammatory DCs, alum acts as an adjuvant by introducing host DNA into th

46 spite its widespread use, the means by which alum acts as an adjuvant remains poorly understood.

47 ared with approved or experimental adjuvants alum, AddaVax, and poly(I.C).

48 arly rules out a role for depot formation in alum adjuvant activity.

49 utaneous immunization with the conjugate and alum adjuvant likewise induced higher antibody titers th

50 LT(G33D) proved superior to standard alum adjuvant regarding the magnitude and breadth of the

51 sponse but the combination of lentiVLPs with Alum adjuvant resulted in a more potent response.

52 responses were superior to those induced by alum adjuvant, and they resulted in enhanced protection

53 ing inactivated yellow fever antigen with an alum adjuvant, induced neutralizing antibodies in a high

54 microg of RSV-PreF antigen, with or without alum adjuvant, or control, and followed for one year for

55 peptides, conjugated to KLH, delivered with alum adjuvant.

56 es of nontargeted NP-protein conjugates with alum adjuvant.

57 for efficacy and has side effects due to its alum adjuvant.

58 antibody isotypes than large doses of OVA in alum adjuvant.

59 rates IFN-beta and neuroantigen (NAg) in the Alum adjuvant.

60 nses to the split vaccine and the effects of alum adjuvant.

61 cultures and adsorbed to aluminum hydroxide (alum) adjuvant.

62 olyvalent, inactivated HRVs plus alhydrogel (alum) adjuvant.

63 idal activity (SBA) against MenC compared to alum adjuvanted vaccine, especially with a low dose of a

64 mulsion were superior to unadjuvanted or MPL-alum-adjuvanted formulations at eliciting a robust cell-

65 nd infants immunized with the same MF59- and alum-adjuvanted HIV envelope vaccines.

66 After alum-adjuvanted immunization, antigen-specific bone marr

67 ells and optimal humoral responses following alum-adjuvanted immunization.

68 induced by adenovirus vector immunization or alum-adjuvanted protein immunization even if CD4(+)T cel

69 induced by CLDC-adjuvanted vaccine than with alum-adjuvanted vaccine.

70 Although alum-adjuvanted vaccines induced modest costimulatory mo

71 st responses compared to those achieved with alum-adjuvanted vaccines.

72 dentify DC-derived IL-2 as a key mediator of alum adjuvanticity in vivo and the Src-Syk pathway as a

73 In this article, we show that alum adjuvanticity requires IL-2 specifically released b

74 Alum adjuvants have been in continuous clinical use for

75 rated into stable emulsion (SE) (GLA-SE) and alum adjuvants in the cotton rat model.

76 otection was observed with both Freund's and alum adjuvants, given subcutaneously and intramuscularly

77 ulated with monophosphoryl lipid A (MPL) and alum adjuvants.

78 by the formulation of SARS-CoV vaccines with alum adjuvants.

79 Aluminum salt (alum) adjuvants have been used for many years as adjuvan

80 i or subcutaneously with aluminum hydroxide (Alum)-adsorbed rBet v 1.

81 ed following two to three immunizations with alum-adsorbed ICC-1132.

82 BALB/c mice were sensitized with alum-adsorbed ovalbumin (OVA) and then challenged with a

83 Only subcutaneous immunization with Alum-adsorbed rBet v 1 and epicutaneous administration o

84 colonization compared with immunization with alum alone.

85 hea and death compared to mice immunzed with alum alone.

86 adjuvant based on a TLR7 agonist adsorbed to alum (Alum-TLR7), which is highly efficacious at enhanci

87 imian immunodeficiency virus (SIV) and gp120 alum (ALVAC-SIV + gp120) equivalent vaccine, but not an

88 Vaccination with IFN-beta + NAg in Alum ameliorated NAg-specific sensitization and inhibite

89 , a metal ionophore; and aluminum hydroxide (alum), an immunological adjuvant.

90 of 20 mug of glycoprotein D from HSV-2 with alum and 3-O-deacylated monophosphoryl lipid A as an adj

91 coinjection of these DNase preparations with alum and Ag reduced the host's immune response to the va

92 We find that alum and an aqueous nanosuspension of GLA synergize to e

93 th wtMVA, MVA-OVA, or PBS, sensitized to OVA/alum and challenged with a diet containing chicken egg w

94 oid (TT) conjugate formulated with adjuvants alum and CpG oligodeoxynucleotide (ODN) generated heroin

95 re, we further investigated the mechanism of alum and DNA's adjuvant function.

96 When used with pure, defined proteins, both alum and emulsion adjuvants are effective at inducing pr

97 adoxically exhibited limited AAI in both OVA-alum and HDM models.

98 Standard ovalbumin (OVA)-alum and house dust mite (HDM) bone marrow-derived DC (B

99 ower doses have focused on adjuvants such as alum and MF59, which are currently licensed for influenz

100 ith a soluble truncated gD protein (gD2t) in alum and monophosphoryl lipid A (MPL) elicited high neut

101 accine consisting of glycoprotein D (gD2) in alum and monophosphoryl lipid A (MPL) reduced genital he

102 icle (VLP) vaccine candidate adjuvanted with alum and monophosphoryl lipid A (MPL), blockade Ab titer

103 oxoid A and toxoid B vaccine adjuvanted with alum and oral challenge with C. difficile VPI 10463, C57

104 ontrast, immunization with NP delivered with alum and the detoxified LPS adjuvant, monophosphoryl lip

105 uvants in approved human vaccines, including alum and the oil-in-water-based emulsions MF59 (Novartis

106 mmunized with the combination of gC2/gD2-CpG/alum and the UL19/UL47 adenovirus vectors.

107 the molecular pathways used by DCs to sense alum and, in turn, activate T and B cells.

108 Again, alum and/or CpG adjuvants did not have an effect on the

109 We demonstrate that alum and/or CpG adjuvants induced similar uptake of anti

110 oth the humoral (>32 times of IgG1 levels vs alum) and the cell-mediated immune responses against the

111 Aluminum salts (alum) and the oil-in-water emulsion MF59 are safe and ef

112 profiled different TLR-independent (MF59 and alum) and TLR-dependent (CpG, resiquimod, and Pam3CSK4)

113 milieus: OVA protein in CFA, aluminum salts (Alum), and Schistosoma mansoni eggs (Sm Egg).

114 30 microg RSV-PreF/alum, 60 microg RSV-PreF/alum, and 60 microg RSV-PreF/nonadjuvant groups.

115 tivated virus with adjuvants, either MF59 or alum, and was associated with stimulation of the CD4 but

116 ein immunization with ALVAC-SIV and gp120 in alum, and we challenged them with SIV(mac251) at either

117 ere cultured in autologous plasma; levels of alum- and TLR agonist-induced cytokines and costimulator

118 d vaccinia Ankara (a poxvirus); protein with alum; and protein in the squalene oil-in-water adjuvant

119 uminium adjuvants, typically referred to as 'alum', are the most commonly used adjuvants in human and

120 d; (ii) immunized with gC2/gD2, with CpG and alum as adjuvants; (iii) immunized with the UL19/UL47 ad

121 The use of GAD-alum as compared with placebo did not affect the insulin

122 fore ultrafiltration, was compared with only alum as pretreatment.

123 was apparent for immunization with VLP-NP or alum as the adjuvant.

124 Many vaccines include aluminum salts (alum) as adjuvants despite little knowledge of alum's fu

125 , using either U1 RNA or aluminum hydroxide (alum) as the adjuvant.

126 extensive usage of insoluble aluminum salts (alum) as vaccine adjuvants, the molecular mechanisms und

127 We demonstrate that alum, as well as other sterile particulates, such as uri

128 e was dependent on mucosal sensitization, as alum/Aspergillus-sensitized mice that were rechallenged

129 IMQs were more potent and effective than alum at inducing TNF and IL-1beta from monocytes.

130 lone or the mineral salt aluminum hydroxide (alum) at the muscle injection site over multiple timepoi

131 During jar tests on alum-based drinking water treatment, dissolved Al determ

132 IFN-beta/Alum-based vaccination exhibited hallmarks of infectious

133 lO (1 mg/l as active Cl) in combination with alum, before ultrafiltration, was compared with only alu

134 minimal gene upregulation induced by SE and alum, both GLA and GLA-SE triggered MyD88- and TRIF-depe

135 creted mainly IL-2 after priming with OVA in alum, but were biased toward IFN-gamma secretion when pr

136 Therefore, alum by itself poorly induces Mo-DCs to migrate to drain

137 hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell function in patients with r

138 Here, we show that alum cannot elicit reactive neutrophilias in IL-1R type

139 of IFN-gamma-inducible protein decreased by Alum cotreatment.

140 e candidates alone or adjuvanted with either alum, CpG, or Advax, a new delta inulin-based polysaccha

141 eur's canarypox vector (ALVAC)-HIV and gp120 alum decreased the risk of HIV acquisition in the RV144

142 ld-type and Nlrp3(-/-) mice in either acute (alum-dependent) or chronic (alum-independent) OVA models

143 removal of the injection site and associated alum depot, as early as 2 h after administration, had no

144 nes, vaccination with TGF-beta + MOG35-55 in Alum did not increase Treg percentages in vivo.

145 Treatment with GAD-alum did not significantly reduce the loss of stimulated

146 In the absence of alum, DIV vaccine performed poorly in young animals chal

147 ro, it has been repeatedly demonstrated that alum does not require intact Toll-like receptor signalli

148 several 'delivery system' adjuvants such as alum, emulsions, liposomes, and polymeric particles.

149 wed that addition of small amounts of LPS to alum enhanced Mo-DC migration.

150 han conventional DCs, the addition of LPS to alum enhanced the overall immunogenicity of Ags presente

151 velopment of the immune response elicited by alum-enhanced vaccination and suggest that therapeutic i

152 igen and/or inflammation are responsible for alum enhancement of antigen presentation and subsequent

153 ts: four doses of GAD-alum, two doses of GAD-alum followed by two doses of placebo, or four doses of

154 re sensitized with intraperitoneal ovalbumin-alum, followed by intranasal challenge with ovalbumin al

155 Sensitization to ovalbumin (OVA) in alum, followed by three airway exposures to OVA, induced

156 r Abeta(1-42) formulated with aluminum salt (Alum) for 2.4 years (25 vaccinations).

157 red all three components, IFN-beta, NAg, and Alum, for inhibition of experimental autoimmune encephal

158 We hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell

159 Whereas unadjuvanted or alum-formulated vaccines were associated with significan

160 In a previous phase I trial, an alum formulation of ICC-1132, a malaria vaccine candidat

161 The GMZ2/alum formulation showed good safety, tolerability, and i

162 a modest and selected role for NLRP3 in the alum-free OVA model.

163 mations in immunogenic formulations based on alum, Freund's adjuvant, or two different types of lipos

164 ent antigen given in four typical adjuvants: alum, Freund's complete adjuvant, Freund's incomplete ad

165 Alum greatly enhances priming of endogenous CD4 and CD8

166 ter a 1:16 dilution of sera from mice in the alum group.

167 ntially supported CD25 upregulation (CFA and Alum > Sm Egg).

168 on to GTF compared to animals immunized with alum-GTF alone.

169 Contrary to expectation, animals receiving alum-GTF plus bacterial DNA (P. gingivalis in particular

170 m hydroxide (alum) with buffer, alum-GTF, or alum-GTF together with either Escherichia coli DNA, Fuso

171 se was also observed after administration of alum-GTF with the P. gingivalis DNA either together or s

172 with aluminum hydroxide (alum) with buffer, alum-GTF, or alum-GTF together with either Escherichia c

173 However, alum hardly induces T helper 1 (Th1) immune responses th

174 ant, which enhances the immune functions and alum has been widely used in human immunization.

175 In an OVA/Alum i.p.-sensitization mouse model, Amb-APE was intrana

176 orrelated with a complete protection from TT/Alum/IL-36beta-induced mortality.

177 f its ability to cleave DNA, suggesting that alum improves CD4 responses to Ag via a pathway other th

178 t influenza virus split vaccine with MF59 or alum in CD4 knockout (CD4KO) and wild-type (WT) mice.

179 allergic asthma was developed with ovalbumin-alum in female Cd39 wild type (Cd39(+/+) ) and deficient

180 ne adjuvants, namely CAF01, IC31, GLA-SE and Alum in mice.

181 interleukin-18 by macrophages in response to alum in vitro required intact inflammasome signalling.

182 Alum increased antibody titers; MF59(R) induced strong a

183 in either acute (alum-dependent) or chronic (alum-independent) OVA models.

184 ith cholera toxin provided 56% efficacy; and alum induced a Th2-type response that protected 62 to 68

185 The novel finding that alum induced HSP70 suggests that stress is involved in t

186 The combination of IL-36beta and TT/Alum induced the rapid production of TNF-alpha and IFN-g

187 with Ag-SP before or after initiation of OVA/alum-induced allergic airway inflammation or peanut-indu

188 mice showed markedly reduced severity in OVA/alum-induced allergic airway inflammation.

189 in a murine model of Th2-mediated ovalbumin/alum-induced allergic airway inflammation.

190 We compared the severity of OVA/alum-induced allergic lung inflammation in WT BALB/c mic

191 cells was both necessary and sufficient for alum-induced HSC, multipotent progenitor, and granulocyt

192 Alum-induced IL-1beta and IL-18 production was not due t

193 essary, but indirect, role in the support of alum-induced neutrophilias by expanding both pluripotent

194 cell recruitment and IL-1beta generation in alum-induced peritonitis, which is a typical IL-1 signal

195 and peritoneal IL-1beta production following Alum-induced peritonitis.

196 e show that, in human and mouse macrophages, alum-induced secretion of IL-1beta, IL-18, and IL-33 is

197 Vaccine efficacy was associated with alum-induced, but not with MF59-induced, envelope (Env)-

198 Within hours of exposure, alum induces a type 2 innate response characterized by a

199 Alum induces eosinophil accumulation partly through the

200 ation of Ag adsorbed to alum, we showed that alum-injected muscles contained large numbers of convent

201 In alum-injected muscles, Mo-DCs were as numerous as conven

202 Alum is a neonatal adjuvant but might confer a T(H)2 bia

203 Although alum is known to induce the production of proinflammator

204 Recently, it was shown that injected alum is rapidly coated with host chromatin within mice.

205 production elicited by vaccines that contain alum is significantly impaired in NLRP3-deficient mice.

206 Alum is the only adjuvant approved for routine use in hu

207 Alum is the only licensed adjuvant by Food and Drug Admi

208 Aluminum hydroxide (Alum) is the only adjuvant approved for routine use in h

209 CFA and Alum led to robust Treg accumulation, with >50% of all s

210 h a soluble peptide, Leu-Leu-OMe, mimics the alum-like form of necrotic cell death in terms of cathep

211 adjuvant effects, Leu-Leu-OMe replicated an alum-like immune response in vivo, characterized by dend

212 a variety of adjuvant formulations including alum, liposomes, and oil-in-water emulsions to determine

213 tigation were to examine the hypothesis that alum-mediated adjuvanticity is a function of stress and

214 whereas cathepsins B and S were required for alum-mediated necrosis.

215 , but did not affect T-independent type 1 or alum-mediated T-dependent humoral responses or TLR-indep

216 -head comparison of five different adjuvants Alum, MF59(R), GLA-SE, IC31(R) and CAF01 in mice and com

217 etween adults and infants immunized with the alum/MNrgp120 vaccine (gp120 median fluorescence intensi

218 s of OVA-specific IgE compared to the WT-OVA/alum model.

219 Proinsulin/alum monotherapy failed to correct hyperglycemia, while

220 Proinsulin/alum monotherapy induced interleukin (IL)-4- and IL-10-s

221 These two groups were boosted with MPL and alum (MPL-alum) together with either formalin-inactivate

222 ith RG1-VLP adjuvanted with human-applicable alum-MPL (aluminum hydroxide plus 3-O-desacyl-4'-monopho

223 combining ivag HPV-gBsec/gDsec and i.m. gD2t-alum-MPL improved survival and reduced genital lesions a

224 ness of different vaccines, we tested gD2 in alum/MPL, gD2 in Freund's adjuvant, and dl5-29 (a replic

225 ived 4 doses of ALVAC-HIV-1/AIDSVAX B/B with alum (n=9) or placebo (n=13) between 0 and 12 weeks of a

226 =48), VaxGen rgp120 with aluminum hydroxide (alum; n=49), or placebo (n=19) between 0 and 20 weeks of

227 tion of SHIP show poor antibody responses on Alum/NP-CGG immunization and diminished Th2 cytokine pro

228 vivo are not required for adjuvant effect of alum on endogenous T and B cell responses.

229 ith PcpA and alum versus mice immunized with alum only.

230 ent in the muscle induced by MF59 but not by alum or incomplete Freund's adjuvant.

231 d by ALVAC-SIV/gp120 vaccination, given with alum or MF59 adjuvant, to capture infectious SIVmac251 a

232 d whether the addition of a gp120 protein in alum or MVA-expressed secreted gp140 (MVAgp140) could im

233 In contrast, the adjuvant effects of Alum or parent MDP show a strong Th2-bias (dominance of

234 alpha11-88x8 or alpha11-88x5 adjuvanted with alum or the licensed HPV vaccines and challenged intrava

235 At such low doses, the conventional adjuvant alum or the molecular adjuvants monophosphoryl lipid A (

236 CD40L on T cells in the animals treated with alum or the stress agents mediate the interactions betwe

237 ularly with monophosphoryl lipid A (MPL) and alum, or gC2 and gD2 were produced in glycoengineered Pi

238 poly)glycerolphosphate and tetanus toxoid in alum plus CpG-oligodeoxynucleotides produced high second

239 presensitized with intraperitoneal ovalbumin/alum plus oral ovalbumin.

240 cells (OTI) and the response to subcutaneous alum-precipitated ovalbumin was followed in the draining

241 factors during a T-dependent Ab response to alum-precipitated protein in mouse lymph nodes.

242 dA IgG titers were enhanced by administering alum-precipitated protein, a modest additional protectio

243 Th2 Ags such as alum-precipitated proteins and helminths induce IgG1, wh

244 DC into the ocular mucosa of ovalbumin (OVA)/alum-primed mice.

245 VAC vaccine coupled with the monomeric gp120/alum protein have decreased the risk of HIV and SIV acqu

246 t, cells costimulated with TLR agonists plus Alum released large amount of IL-1beta and IL-18.

247 ying the stimulation of the immune system by alum remains unknown.

248 S. Typhi(F1), as opposed to priming with F1-alum, resulted in a more balanced IgG2a/IgG1 profile, en

249 the ability of DNase preparations to inhibit alum's adjuvant activity.

250 DNA in the coating chromatin contributed to alum's adjuvant activity.

251 um) as adjuvants despite little knowledge of alum's functions.

252 ghly effective in attenuating the AHR of OVA/alum-sensitized TLR4-deficient mice.

253 mally after stimulation with ATP, nigericin, alum, silica, flagellin, or cytoplasmic DNA, indicating

254 The laboratory scale alum sludge-based intermittent aeration constructed wetl

255 ectious tolerance, because IFN-beta + OVA in Alum-specific vaccination inhibited EAE elicited by OVA

256 4] agonist glucopyranosal lipid A [GLA] plus alum, squalene-oil-in-water emulsion, and GLA plus squal

257 in our laboratories (SMIP.7-10) adsorbed to alum, the five antigens provided close to 100% protectio

258 When formulated with alum, the monomeric cysteine mutants induced a similar i

259 atible with many vaccine adjuvants including alum, the most common adjuvant used in the vaccine marke

260 diated cell death in immunity and found that alum, the most commonly used adjuvant worldwide, trigger

261 Compared with alum, the protective efficacy of the pandemic H1N1 influ

262 While with fresh alum, the removal efficiencies of total suspended solids

263 T follicular helper (TFH) and Th1 cells than alum, the SE alone, or GLA without SE.

264 mall molecule immune potentiator (SMIP) onto alum, thereby enhancing co-delivery with antigen.

265 Ultimately, compared with alum, this system offered superior protection in a mouse

266 Finally, we demonstrate that Alum-TLR7 adjuvant effect requires a functional TLR7.

267 Alum-TLR7 also drives antibody response towards Th1 isot

268 Taken together, our data support the use of Alum-TLR7 as adjuvant for glycoconjugate vaccines.

269 We found that in a mouse model Alum-TLR7 greatly improved potency of a CRM197-MenC vacc

270 Furthermore, we found that Alum-TLR7 increases anti-polysaccharide immune response

271 ugate vaccines in humans, we investigated if Alum-TLR7 is able to improve immunogenicity of this clas

272 nt based on a TLR7 agonist adsorbed to alum (Alum-TLR7), which is highly efficacious at enhancing imm

273 nide as adjuvants to favor a Th1 response or alum to elicit a Th2 response.

274 ly as a bivalent vaccine with Iscomatrix and alum to HSV-1-naive or -seropositive guinea pigs.

275 o groups were boosted with MPL and alum (MPL-alum) together with either formalin-inactivated mock HSV

276 h four different human-compatible adjuvants (alum, Toll-like receptor 4 [TLR-4] agonist glucopyranosa

277 ibody responses to tier 2 HIV-1 strains with alum treatment alone in the absence of Env.

278 y cytokines such as IL-8 was not affected by Alum treatments.

279 of three study treatments: four doses of GAD-alum, two doses of GAD-alum followed by two doses of pla

280 r to the results with the standard adjuvant, alum, U1 RNA coadministered with NP-KLH enhanced product

281 IFN-beta + NAg in Alum vaccination elicited elevated numbers and percentag

282 this study indicates that IFN-beta + NAg in Alum vaccination elicits NAg-specific, suppressive CD25(

283 Unlike IFN-beta + NAg in Alum vaccines, vaccination with TGF-beta + MOG35-55 in A

284 om the lungs of mice immunized with PcpA and alum versus mice immunized with alum only.

285 ve FOXP3(+) Tregs in vitro in the absence of Alum via a mechanism that was neutralized by anti-TGF-be

286 The toxicity of IL-36beta + TT/Alum was abrogated by the administration of a neutralizi

287 A parenteral booster with purified PA83 plus alum was given to rhesus macaques on days 42 and 225; cy

288 We found that the inflammation induced by alum was unchanged in caspase-1-deficient mice, which ca

289 ergic inflammatory response to ovalbumin and alum was unimpaired.

290 nderstand more about how the body recognizes alum we characterized the early innate and adaptive resp

291 he primary IgE response to i.p.-injected OVA-alum, we investigated the gammadelta T cells involved.

292 After i.m. administration of Ag adsorbed to alum, we showed that alum-injected muscles contained lar

293 uantity and quality than aluminum hydroxide (alum), which is currently the most widely used adjuvant

294 nd adjuvanticity, commensurate with those of alum, which may provide an alternative strategy in devel

295 se BZN-phosphonates are highly adsorbed onto alum, which significantly reduced systemic exposure and

296 nse to a subsequent parenteral boost with F1-alum, which surpassed those of mice primed and boosted w

297 ctedly, the combination of IL-36beta with TT/Alum, which was well tolerated in AD mice, proved toxic

298 The substitution of alum with the more immunogenic MF59 adjuvant is under co

299 rats were injected with aluminum hydroxide (alum) with buffer, alum-GTF, or alum-GTF together with e

300 ct of combining a prototypic ABT, proinsulin/alum, with GABA treatment in newly diabetic NOD mice.